Financial guidance for 2026 maintained as Myriad Genetics delivers first quarter results

Financial guidance for 2026 maintained as Myriad Genetics delivers first quarter results
Myriad Genetics confirms 2026 outlook

Myriad Genetics has released its financial results for the first quarter ended March 31, 2026, and reaffirmed its guidance for the full year 2026.

The company continues to demonstrate confidence in its outlook, maintaining projections despite market uncertainties. Investors and analysts are likely to assess the impact of these results on the company’s stock performance and future strategy in the diagnostics sector.

Earlier this year, Myriad Genetics secured a spot on Forbes' list of America's Best Employers for Company Culture in 2026 based on employee feedback. The company also announced the launch of its FirstGene Multiple Prenatal Screen at a Washington, D.C. symposium. Both developments have contributed to the company's recent corporate activity.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.